NASDAQ:RGLS 27 June 2025

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.

27 June 2025

Biotechnology·LSE:AZN·NASDAQ:ABEO·NASDAQ:ITCI·NASDAQ:PRME·NASDAQ:RGLS·NASDAQ:RGNX·NASDAQ:VRTX·NASDAQ:WVE·NYSE:CTLT·NYSE:JNJ·XETRA:MRK

ASX Miners Face Diesel Cost Surge Amid Strait of Hormuz Closure
March 24, 2026, 11:36 PM EDT. Australia's mining sector is confronting significant challenges as diesel prices soar 75% to nearly $3 per litre, fueled by the Iran-strained Strait of Hormuz closure disrupting 20% of global energy supply. With major diesel exporters like China halting shipments, brokers advise investors to favour miners with underground operations over open-cut projects. This preference reflects the greater fuel intensity of open-cut mining, rendering those stocks more vulnerable amid the surge. The sector's bear market deepens as operators grapple with rising input costs amid tight energy supply conditions.